According to the disclosure policy of the American Academy of CME, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any significant relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for fair balance, scientific objectivity of studies reported, and patient care recommendations. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.

It is the policy of the Academy to ensure balance, independence, objectivity, and scientific rigor in all sponsored educational activities. Any and all financial relationships between faculty and the commercial sponsors of the CE activity, and products being discussed, is to be disclosed by the faculty to the attendees at the time of the activity. Discussion of any non-FDA-approved product or device shall also be made known to the audience.

Planning Committee
John P. Bilezikian, MD
Professor of Medicine
Columbia University College of Physicians and Surgeons;
Chief, Division of Endocrinology
Director, Metabolic Bone Diseases Program
Columbia-Presbyterian Medical Center
New York, New York

Disclosure: Dr. Bilezikian has received grant/research support from Alliance for Better Bone Health (Proctor & Gamble Pharmaceuticals and sanofi-aventis); has been a consultant for Radius Ventures; and has served on the advisory boards of Alliance for Better Bone Health (Proctor & Gamble Pharmaceuticals and sanofi-aventis), Amgen, Eli Lilly and Co., and Merck & Co.

Ernesto Canalis, MD
Director of Research
Saint Francis Hospital and Medical Center
Hartford, Connecticut;
Professor of Medicine
University of Connecticut School of Medicine
Farmington, Connecticut

Disclosure: Dr. Canalis has received grant/research support from Acceleron Pharma;  has been a consultant for Acceleron Pharma, Eli Lilly & Co., and Novartis Pharmaceuticals Corp.; and has served on the speakers’ bureau of GlaxoSmithKline Pharmaceuticals, Merck & Co., Novartis Pharmaceuticals Corp., Proctor & Gamble Pharmaceuticals, Roche Laboratories, and sanofi-aventis.

Nelson B. Watts, MD
Professor of Medicine
University of Cincinnati College of Medicine;
Director
University Bone Health and Osteoporosis Center
Cincinnati, Ohio

Disclosure:  Dr. Watts has received grant/research support from Amgen, Eli Lilly and Co., MicroMRI, Novartis Pharmaceuticals Corp., Proctor & Gamble Pharmaceuticals, Radius Ventures, sanofi-aventis, and Solvay Pharmaceuticals; has been a consultant for Amgen, Eli Lilly and Co., Novartis Pharmaceuticals Corp., Proctor & Gamble Pharmaceuticals, Roche Laboratories, and sanofi-aventis; and has received honoraria from Amgen, Novartis Pharmaceuticals Corp., Proctor & Gamble Pharmaceuticals, and sanofi-aventis.

Independent Clinical Reviewer
Jeffrey P. Levine, MD, MPH
Associate Professor / Master Educators' Guild
Director, Women's Health Programs
Department of Family Medicine
UMDNJ-Robert Wood Johnson Medical School
New Brunswick, New Jersey

Disclosure:  Dr. Levine has served on the scientific advisory boards of Eli Lilly and Co., Novartis Pharmaceuticals, Proctor & Gamble Pharmaceuticals, and Wyeth Pharmaceuticals.

Target Audience

This educational activity is designed for primary-care physicians and other health care professionals interested in or involved with the management of patients with a diagnosis of or at risk for osteoporosis

Learning Objectives
Upon completion of this CME program, the participant should be able to:

•		Identify the risk factors associated with osteoporosis which are useful in predicting fracture risk.
•		Describe the clinical evaluation of a patient at risk of developing osteoporosis including interpretation of clinical data and bone density tests.
•		List the different mechanisms of action and associated benefits and limitations of each agent used to prevent fractures.
•		Evaluate information from clinical studies on anti-resorptive agents and consider how to integrate them into clinical decision making.

Credits Available

Physicians - Maximum of 1.5 AMA PRA Category 1 Credits™ for physicians

All other health care professionals completing continuing education credit for this activity will be issued a certificate of participation.

Physicians should only claim credit commensurate with the extent of their participation in the activity.

Accreditation Statements

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of The American Academy of CME, Inc. and CaseMed/ Healthcare First. The American Academy of CME, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The American Academy of CME, Inc. designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits.^TM Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity: smoylan@academycme.com.

Follow these steps to earn CME credit:

1. Read the target audience, learning objectives, and author disclosures.
2. Study the educational content within the simulated cases.
3. Complete the evaluation provided.
4. Print your certificate.

Hardware/Software Requirements

The simulation requires version 4.x browsers or higher from Microsoft or Netscape or Mozilla FireFox version 1.5.x or higher. Certain activities may require additional software to view multimedia, presentation or printable versions of their content.
There are no specific hardware requirements.

Legal Disclaimer

This software and documentation is a convenient compilation of published resources provided as reference material and/or instructional aides for physicians and other health care professionals in exercising their independent judgment for the purpose of treating patients. Every possible effort is made to ensure the material presented in the software and documentation accurately and reliably reflects published standards of care, however, recommendations for care and treatment change rapidly, and opinions can be controversial. Mention of specific drugs or products in this software and documentation does not constitute endorsement by the American Academy of CME (the Academy), Healthcare First/CaseMed, TheraSim, Inc., the authors, or reviewers. With regard to specific drugs or products, physicians and other authorized health care professionals are advised to consult their normal high quality resources before prescribing to their patients. Therefore, physicians and other health care professionals are required to consult all other reliable sources and confirm the information contained in this software and documentation. It is up to the individual physician or other health care professional to use his or her best medical judgment in determining the appropriate patient care or treatment consistent with the applicable standard of care, because no single reference or service can take the place of medical training, education, experience, and the proper application thereof.

Some of the information contained in this software and documentation may cite the use of a particular drug or dosage, for an indication, or in a manner other than recommended or FDA-approved. Therefore, the manufacturer's package inserts should be consulted for complete prescribing information.

The Academy has maintained responsibility for the development of content within the essentials and policies of the Accreditation Council for Continuing Medical Education (ACCME). The material presented here does not necessarily reflect the views of the Academy, Healthcare First/CaseMed, TheraSim, Inc., or production staff.